ArticleNPJ breast cancer2024

Clinical and immune responses to neoadjuvant fulvestrant with or without enzalutamide in ER+/Her2- breast cancer.

Anthony D Elias et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.